Back to Search Start Over

Mesoporous Bioactive Glasses in Cancer Diagnosis and Therapy: Stimuli‐Responsive, Toxicity, Immunogenicity, and Clinical Translation.

Authors :
Sharifi, Esmaeel
Bigham, Ashkan
Yousefiasl, Satar
Trovato, Maria
Ghomi, Matineh
Esmaeili, Yasaman
Samadi, Pouria
Zarrabi, Ali
Ashrafizadeh, Milad
Sharifi, Shokrollah
Sartorius, Rossella
Dabbagh Moghaddam, Farnaz
Maleki, Aziz
Song, Hao
Agarwal, Tarun
Maiti, Tapas Kumar
Nikfarjam, Nasser
Burvill, Colin
Mattoli, Virgilio
Raucci, Maria Grazia
Source :
Advanced Science; 1/14/2022, Vol. 9 Issue 2, p1-44, 44p
Publication Year :
2022

Abstract

Cancer is one of the top life‐threatening dangers to the human survival, accounting for over 10 million deaths per year. Bioactive glasses have developed dramatically since their discovery 50 years ago, with applications that include therapeutics as well as diagnostics. A new system within the bioactive glass family, mesoporous bioactive glasses (MBGs), has evolved into a multifunctional platform, thanks to MBGs easy‐to‐functionalize nature and tailorable textural properties—surface area, pore size, and pore volume. Although MBGs have yet to meet their potential in tumor treatment and imaging in practice, recently research has shed light on the distinguished MBGs capabilities as promising theranostic systems for cancer imaging and therapy. This review presents research progress in the field of MBG applications in cancer diagnosis and therapy, including synthesis of MBGs, mechanistic overview of MBGs application in tumor diagnosis and drug monitoring, applications of MBGs in cancer therapy (particularly, targeted delivery and stimuli‐responsive nanoplatforms), and immunological profile of MBG‐based nanodevices in reference to the development of novel cancer therapeutics. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
21983844
Volume :
9
Issue :
2
Database :
Complementary Index
Journal :
Advanced Science
Publication Type :
Academic Journal
Accession number :
154689376
Full Text :
https://doi.org/10.1002/advs.202102678